Drug maker Merck & Co. likely won’t know if it can market its cervical-cancer vaccine to older women until the end of the year, reports The Wall Street Journal.

The Whitehouse Station, N.J.-based company (NYSE: MRK) had sought U.S. Food and Drug Administration approval to market its vaccine Gardasil to women between the ages of 27 and 45. The drug is currently approved for females ages 9 to 26. Merck had expected a decision from the FDA by next week but now says it expects a decision by the end of the year.

Read more: Merck: FDA decision delayed on cervical-cancer vaccine Gardasil – Triangle Business Journal

Feel good and keep smiling! Pattie

Leave a Reply